Yi Liu, Zong Bao Wang, Wei Dong Yin, Qin Kai Li, Man Bo Cai, Jian Yu, Hong Guang Li, Chi Zhang, Xiu Hong Zu
Index: Lipids Health Dis. 10 , 117, (2011)
Full Text: HTML
The role of renal lipoprotein lipase (LPL) per se in kidney diseases is still controversial and obscure. The purpose of this study was to observe the preventive effects of Ibrolipim, a LPL activator, on lipid accumulation and LPL expression in the kidneys of minipigs fed a high-sucrose and high-fat diet (HSFD).Male Chinese Bama minipigs were fed a control diet or HSFD with or without 0.1 g/kg/day Ibrolipim for 5 months. Body weight, plasma glucose, insulin, lipids, LPL activity, and urinary microalbumin were measured. Renal tissue was obtained for detecting LPL activity and contents of triglyceride and cholesterol, observing the renal lipid accumulation by Oil Red O staining, and examining the mRNA and protein expression of LPL by real time PCR, Western Blot and immunohistochemistry.Feeding HSFD to minipigs caused weight gain, hyperglycemia, hyperinsulinemia, hyperlipidemia and microalbuminuria. HSFD increased plasma LPL activity while it decreased the mRNA and protein expression and activity of LPL in the kidney. The increases in renal triglyceride and cholesterol contents were associated with the decrease in renal LPL activity of HSFD-fed minipigs. In contrast, supplementing Ibrolipim into HSFD lowered body weight, plasma glucose, insulin, triglyceride and urinary albumin concentrations while it increased plasma total cholesterol and HDL-C. Ibrolipim suppressed the renal accumulation of triglyceride and cholesterol, and stimulated the diet-induced down-regulation of LPL expression and activity in the kidney.Ibrolipim exerts renoprotective and hypolipidemic effects via the increase in renal LPL activity and expression, and thus the increased expression and activity of renal LPL play a vital role in suppressing renal lipid accumulation and ameliorating proteinuria in diet-induced diabetic minipigs.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Ibrolipim
CAS:133208-93-2 |
C19H20BrN2O4P |
Effects of NO-1886 on inflammation-associated cytokines in h...
2006-07-01 [Eur. J. Pharmacol. 540(1-3) , 139-46, (2006)] |
NO-1886 suppresses diet-induced insulin resistance and chole...
2010-01-01 [J. Endocrinol. 1st ed., 204 , 47-56, (2010)] |
Evaluation of induction potency of new drug candidates on CY...
2009-01-01 [Drug Metab. Pharmacokinet. 24(5) , 446-50, (2009)] |
NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, a...
2006-02-01 [Metab. Clin. Exp. 55(2) , 151-8, (2006)] |
NO-1886, a lipoprotein lipase activator, attenuates vascular...
2007-01-12 [Eur. J. Pharmacol. 554(2-3) , 183-90, (2007)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved